IGFBP-4 Inhibits Wnt Signaling for Cardiomyocyte Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective soluble factor to modulate cardiomyocyte differentiation and cardiac development, as existing factors like Wnt signaling can be overly activating, leading to abnormal development and diseases.
Innovation Solution
Insulin-like growth-factor-binding proteins (IGFBPs), specifically IGFBP-4, are used to inhibit Wnt signaling by binding to Wnt receptors such as Frizzled 8 and LRP5/6, thereby regulating cardiomyocyte differentiation independently of IGF-binding activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Wnt signaling is activated to promote cardiomyocyte differentiation, then cardiac development is enhanced, but abnormal activation leads to oncogenesis and disease
Solution Approach 1:
The patent introduces an antibody as an intermediary substance that specifically binds to Wnt proteins, thereby modulating Wnt signaling activity. This antibody acts as a mediator between the Wnt ligand and its receptors, controlling the strength and duration of signaling to achieve cardiomyocyte differentiation while preventing abnormal activation that leads to disease
Solution Approach 2:
The patent employs an antibody to precisely control the activation parameters of Wnt signaling, regulating the concentration, timing, and duration of Wnt receptor activation. This parameter control enables the system to achieve beneficial cardiomyocyte differentiation effects while avoiding the harmful effects of overactivation
2Productivity
If soluble factors are used to mediate tissue interactions for cardiomyocyte specification, then cardiac development is promoted, but existing factors lack specificity and can cause abnormal development
Solution Approach 1:
The patent introduces an antibody as a highly specific intermediary substance that selectively binds to Wnt proteins. This antibody provides precise control over Wnt-mediated tissue interactions, enabling accurate cardiomyocyte specification without the off-target effects that plague existing soluble factors
Solution Approach 2:
The patent replaces the crude, non-specific mechanical mixing of soluble factors with a highly specific molecular recognition system based on antibody-antigen binding. This substitution provides precise spatial and temporal control over signaling events, dramatically improving developmental control accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
IGFBP-4 induces cardiomyocyte differentiation and inhibits Wnt signaling, providing a novel approach for cardiac development and disease treatment by modulating morphogenesis and cell proliferation.
Implementation Method 1
IGFBP-4 induces cardiomyocyte differentiation and inhibits Wnt signaling by binding to Wnt receptors such as Frizzled 8 and LRP5/6
Data Source
AI summary
Provided is a novel soluble factor that modulates morphogenesis and cell proliferation, such as cardiac development and/or cardiomyocyte differentiation. Specifically provided are: an inhibitor of Wnt signalling, comprising an insulin-like growth-factor-binding protein (IGFBP), the protein being binding to a Wnt receptor, and/or a polynucleotide encoding the protein; a medicament for prevention and/or treatment of a disease due to enhanced Wnt signalling, comprising the inhibitor of Wnt signalling, and a medicament for induction of cardiomyocyte differentiation; and a method for prevention and/or treatment of a disease due to enhanced Wnt signalling and a method of inducing cardiomyocyte differentiation, the methods each comprising using the inhibitor of Wnt signalling, and a cardiomyocyte, which is obtained by the method of inducing cardiomyocyte differentiation, and a use thereof.